Publicacions en col·laboració amb investigadors/es de Hospital Vall d'Hebron (9)

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

2012

  1. Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739

  2. Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon

    Revista Espanola de Patologia

  3. Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia

2011

  1. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178

2007

  1. Update in the management of ovarian and cervical carcinoma

    Clinical and Translational Oncology, Vol. 9, Núm. 7, pp. 443-451

2005

  1. Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: Do we have enough evidence?

    World Journal of Gastroenterology